(Reuters) -Cosmetic drugmaker Evolus reported a fourth-quarter profit versus a year-ago loss on Tuesday, on strong demand for its wrinkle treatment Jeuveau which competes with Botox.
WHY IT’S IMPORTANT
The company has been targeting a younger demographic compared to other companies such as Revance and AbbVie, among others, which typically focus on people in their 40s.
In February, the U.S. FDA approved Evolus’ two new dermal fillers – Evolysse Form and Evolysse Smooth – which are expected to contribute 8%-10% to its total revenue for 2025.
KEY QUOTE
“We are prepared to launch Evolysse in the second quarter and will be making significant investments in medical education and sampling to support our customers and drive adoption,” said CEO David Moatazedi.
BY THE NUMBERS
Evolus reported an adjusted income of $6.7 million in the fourth quarter, compared with a year-ago loss of $3.7 million.
The company sees 2025 revenue between $345 million and $355 million, compared with Wall Street estimates of $351.3 million according to data compiled by LSEG.
The company projects its annual net revenue can reach at least $700 million by 2028.
(Reporting by Christy Santhosh in Bengaluru; Editing by Krishna Chandra Eluri)
Comments